Calculus Capital launches VCT fundraising – providing exposure to a diverse portfolio of entrepreneurial growth companies Calculus Capital has launched a £10 million fundraising for the Calculus VCT, which aims to deliver investors an annual dividend of 4.5% and capital growth. … Continued
Calculus Capital has led a £6m funding round in Arecor, the UK-based biopharmaceutical formulation company, to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The funding also involved Albion Capital and Downing Ventures, with BioScience Managers Limited advising … Continued
John Glencross was asked by BBC Newsnight to comment on the position for investors during the ongoing Brexit negotiations. To watch the short clip please see below.
London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued
CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such … Continued
The Enterprise Investment Scheme Association (EISA) has launched a new membership programme specifically aimed at Financial Planners and Regulated Advisers. And its FREE! Called the Financial Planning Programme, EISA aims to provide all individuals in the financial planning community with a … Continued
The Bioindustry Association held an informative webinar chaired by Calculus Capital Chief Executive John Glencross with panellists Michael Kipping- Innovation Lead at Innovate UK, Oliver Sexton- Investment Director at UK Innovation & Science Seed Fund and Kaivan Faria- Investment Analyst at Newable, on the … Continued
John Glencross, CEO of Calculus Capital discusses in June’s issue of GB Investment Magazine the strength of the UK entrepreneurial economy and how the boost in popularity of VCTs as a complementary product to maxed out pensions, shows that the … Continued
The Prime Minister delivered a speech this week outlining the Government’s Industrial Strategy which aims to tackle the ‘Four Grand Challenges’ facing the world today, along with a target that UK R&D spend reaches 2.4% of GDP by 2027. The … Continued
Calculus Capital has completed a further investment into a growth capital investment round for Mologic alongside Foresight Group, who led the round. Mologic is a Point of Care (POC) diagnostics company that provides Contract Research (CRO) and manufacturing (CMO) services. … Continued
